The short version
The name advertises Fragment 176-191, CJC-1295, Ipamorelin. Those ingredient names describe the listing, not independently verified contents, proportions, compatibility or packaging. Individual ingredient pages are linked below.
A combination needs its own evaluation; ingredient evidence does not establish blend safety or benefit.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- Fragment 176-191 & CJC-1295 & Ipamorelin Blend
- Entry name · The name used for this encyclopedia topic.
No additional name variations have been documented for this entry yet. This is not a claim that none exist.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
What should be clarified before interpreting claims?
Several ingredients act on growth-hormone signaling. An acute hormone change or a study of one ingredient does not establish the benefit or safety of this combination. Clarify DAC status, exact ingredients, and the clinical reason for interpreting hormone measurements.
Identity and evidence scope · Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
Several ingredients act on growth-hormone signaling. An acute hormone change or a study of one ingredient does not establish the benefit or safety of this combination. Clarify DAC status, exact ingredients, and the clinical reason for interpreting hormone measurements.
Research terms in everyday language ↗
This overview explains the advertised combination and points to ingredient research. A comprehensive search for exact-combination trials has not been completed. No clinical combination benefit is asserted.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- A combination overview for Fragment 176-191 & CJC-1295 & Ipamorelin Blend.
- Name variations
- Names you may see and important distinctions
- Source type
- Ingredient source · not combination evidence
- Reference jurisdiction
- Research context; approval is product- and country-specific
Interpret the source in the context of the preparation and route it discusses. A regulatory notice and a controlled clinical trial answer different questions.
Read about each ingredient
Fragment-176-191 · Cjc-1295 · Ipamorelin
These links describe ingredients individually, not evidence for the combination.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
Context for this ingredient only; not evidence of a combination effect.
Context for this ingredient only; not evidence of a combination effect.
For athletes: competition rules are a separate check ↗